Novartis AG Q1 2011 Financial Summary
Business Context and Reporting Period
This Form 6-K reports the unaudited financial results for Novartis AG for the first quarter ended March 31, 2011. The period is characterized by the completion of the merger with Alcon, Inc. on April 8, 2011, creating a new global eye care division. The results reflect strong underlying sales growth, partially offset by the absence of A(H1N1) pandemic flu vaccine sales recorded in the prior year and the impact of currency fluctuations.
Key Financial Metrics
| Metric | Q1 2011 (USD) | Q1 2010 (USD) | % Change (Reported) | % Change (Constant Currency) |
|---|---|---|---|---|
| Net Sales | 14.0 billion | 12.1 billion | +16% | +14% |
| Operating Income | 3.4 billion | 3.5 billion | -3% | 0% |
| Core Operating Income | 4.0 billion | 3.9 billion | +4% | +6% |
| Net Income | 2.8 billion | 2.9 billion | -4% | -1% |
| Core Net Income | 3.4 billion | 3.3 billion | +2% | +4% |
| EPS (Basic) | $1.21 | $1.29 | -6% | -3% |
| Core EPS | $1.41 | $1.45 | -3% | 0% |
| Free Cash Flow | 1.6 billion | 2.9 billion | -44% | N/A |
| Net Debt | 22.3 billion | 14.9 billion (Dec 2010) | N/A | N/A |
Material Changes vs. Prior Period
- Sales Growth: Net sales increased 16% (14% in constant currencies). Excluding A(H1N1) vaccine sales and Alcon, underlying sales grew 10% (8% cc). Recently launched products contributed $3.1 billion, representing 26% of total sales (excluding Alcon).
- Profitability: Reported operating income declined 3% due to the high base from A(H1N1) sales in Q1 2010 and currency headwinds. However, core operating income rose 4% (6% cc). Excluding A(H1N1) and Alcon, underlying operating income increased 25% (30% cc).
- Cash Flow: Free cash flow dropped 44% to $1.6 billion, primarily due to the absence of $1.3 billion in A(H1N1) cash collections from the prior year and increased working capital requirements.
- Debt: Net debt increased to $22.3 billion from $14.9 billion at year-end 2010, driven by the $5.4 billion dividend payment, $2.8 billion in share repurchases, and acquisition costs.
- Divisional Performance:
- Pharmaceuticals: Sales up 7% (5% cc); Core operating income up 8% (11% cc).
- Vaccines & Diagnostics: Sales down 73% due to the lack of A(H1N1) sales; underlying business grew 43% cc.
- Sandoz: Sales up 16% (15% cc); Core operating income up 9% (11% cc).
- Consumer Health: Sales up 11% (9% cc); Core operating income up 24% (30% cc).
- Alcon: Contributed $1.9 billion in sales and $207 million in operating income for the quarter.
Guidance, Outlook, and Risks
- Outlook: Novartis reaffirms expectations for Group net sales to grow around the double-digit mark in 2011. The company aims to improve core operating income margins in constant currencies while absorbing price cuts, generic competition, and the loss of A(H1N1) sales.
- Currency Impact: If Q1 exchange rates prevail, the full-year impact is estimated at +3% on sales and -2% on operating income.
- Alcon Integration: The merger is expected to be approximately 4% dilutive to basic EPS and 1% dilutive to core EPS in 2011, though share repurchases are mitigating this. Annual cost synergies are expected to exceed $300 million.
- Innovation Pipeline: Key approvals include Gilenya (EU) for multiple sclerosis and Lucentis (EU) for diabetic macular edema. Promising Phase III data was reported for INC424 (myelofibrosis) and Afinitor (neuroendocrine tumors).
- Risks: Significant legal proceedings remain, including Zometa/Aredia product liability litigation and wage/hour class actions. Regulatory delays and generic competition pose ongoing risks to revenue.
Investor Verification Checklist
- Verify the sustainability of the 14% constant currency sales growth excluding the one-time A(H1N1) impact.
- Monitor the execution of Alcon integration and the realization of projected $300 million+ annual cost synergies.
- Assess the impact of the $22.3 billion net debt level on future interest expenses and credit ratings (currently double-A).
- Track the progress of key pipeline assets (Gilenya, Lucentis, Afinitor) and their contribution to future revenue.
- Review the status of ongoing litigation, particularly Zometa/Aredia and wage/hour cases, for potential future provisions.